Legal experts warn the ruling opens the door for challenges to other approved medicines in the US and could also stifle development of future drugs.
I. Glenn Cohen, a Harvard Law School professor, told BBC News the pharmaceutical industry could be wary of more legal challenges, particularly to treatments that have become political flashpoints in the US, like transgender medical treatment and Covid-19 vaccines.